Two Hoosier Cancer Research Network studies, GU14-182 and MEL17-309, will be presented during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, in Chicago.

HCRN GU14-182, a randomized, double-blinded, phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer, will be featured during an oral abstract session on Monday, June 3. The multi-center study is led by Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai.

Session Details:

• Oral Abstract Session: Genitourinary (Nonprostate) Cancer
• Date/Time: Monday, June 3, 8:00 – 11:00 AM CT
• Location: Arie Crown Theater
• Abstract: J Clin Oncol 37, 2019 (suppl; abstr 4504)

HCRN MEL17-309, a phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma, will be presented during a poster session on Monday, June 3. The study is led by Suthee Rapisuwon, MD, of the Georgetown Lombardi Comprehensive Cancer Center.

Session Details:

• Poster Session: Melanoma/Skin Cancers
• Date/Time: Monday, June 3, 1:15 – 4:15 PM CT
• Location: Hall A: Poster Board #170a
• Abstract: J Clin Oncol 37, 2019 (suppl; abstr TPS9604)

HCRN invites all ASCO attendees to visit stop by our booth (Booth #24118) in the exhibit hall located in McCormick Place South, Hall A.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 210 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,500 subjects have participated in Hoosier Cancer Research Network clinical trials.